Oral Cancer  >>  Erbitux (cetuximab) 
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
2018-003589-15: Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial Elettrochemioterapia come trattamento di prima linea nel carcinoma a cellule squamose ricorrenti del cavo orale e dell'orofaringe: uno studio controllato randomizzato

Not yet recruiting
2
96
Europe
Bleoprim, CarboPlatino, Fluorouracile, Erbitux, CISPLATINO, Powder for injection, Infusion, Bleoprim, Carboplatino, Fluorouracile Teva, Erbitux, CISPLATINO TEVA
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
carcinoma of the oral cavity and oropharynx neoplasia del cavo orale e orofaringe, Progressive disease (relapse on T and N0) in the oral cavity and oropharynx Malattia progressiva (recidiva sul T ed N0) nel cavo orale e orofaringe, Diseases [C] - Cancer [C04]
 
 
NCT03082534: Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Checkmark Results in combination with cetuximab for recurrent/metastatic SCCHN
Jul 2021 - Jul 2021: Results in combination with cetuximab for recurrent/metastatic SCCHN
Active, not recruiting
2
78
US
Pembrolizumab, Cetuximab, Keytruda®, Erbitux®
University of California, San Diego, Merck Sharp & Dohme LLC
HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
11/23
05/24
MCC-19178, NCT03370276: Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Active, not recruiting
1/2
95
US
Nivolumab, Opdivo, Cetuximab, Erbitux
H. Lee Moffitt Cancer Center and Research Institute, James and Esther King Biomedical Research Program, Eli Lilly and Company, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Paranasal Sinus, Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer, Head and Neck Carcinoma
09/21
08/24

Download Options